The GMR Clinical Trials Unit will soon be recruiting for the following lung clinical trial:
protocol: CA245-0001 (PI: Dr Kenneth O’Byrne)
Protocol Title: A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS)
Lay Title: BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS)
Click here for more information
PROTOCOL: TACTI-004 (pi: Dr Kenneth O’Byrne)
Protocol Title: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy.
Lay Title: Study of Eftilagimod Alfa (Efti) in Combination with Pembrolizumab and Chemotherapy Versus Placebo in Combination with Pembrolizumab and Chemotherapy in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Click here for for information
PROTOCOL: 20200041 (PI: Dr kenneth o’byrne)
Protocol Title: A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Lay Title: Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First-Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLphi-305).
Click here for more information
Protocol: ca224-1093 (PI: Dr kenneth o’byrne)
Protocol Title: A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression of 1% to 49%.
Lay Title: A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/ Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% (RELATIVITY1093)
Click here for more information